Abbott to Acquire Bigfoot Biomedical to Develop Personalized, Connected Solutions for Diabetes
Shots:
- Abbott to acquire Bigfoot Biomedical to develop personalized, connected solutions for diabetes patients & the transaction is expected to close in Q3’23. Abbott has a longstanding relationship with Bigfoot going back to 2017
- The recent acquisition will bring together two leaders in different aspects of diabetes care: CGM and insulin injection support to develop connected solutions for diabetes management
- Bigfoot developed Bigfoot Unity, a smart insulin management system that exclusively works with Abbott's FreeStyle Libre technology. It includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support patients, incl. through remote care
Ref: PRNewswire | Image: Bigfoot Biomedical
Related News:- Boehringer Ingelheim’s Senvelgo (velagliflozin) Receives the US FDA’s Approval as the First Oral Liquid Medication for Diabetes in Cats
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
